PapilloCheck® HPV-Screening
Donwload the latest brochures and Flyers directly on your personal computer

DNA-Chip for the identification of 24 types of genital HPV

PapilloCheck® features:

  • DNA-Chip for the type-specific identification of 18 high-risk and 6 low-risk types of HPV
  • For primary or secondary cervical cancer screening
  • Certified In-vitro-Diagnostica (IVD), registred in the EU for the qualitative detection of HPVs from clinical specimens

Cervical cancer is the second most common cancer in women worldwide, with almost 471,000 new cases and 233,000 deaths annually. In Europe there are 60,000 new cases and almost 30,000 deaths each year.

Since its introduction, the Pap cytology has significantly decreased cervical cancer in developed countries due to screening programs and advances in the treatment of early-stage disease.

However, during the last 20 years the incidence and mortality rates of cervial cancer did not drop further, but remained unchanged. The rather low sensitivity of the Pap cytology, which is in the range of 43.5% - 58%, is one reason for the observed stagnation in cervical cancer decline. In addition, Pap cytology is limited since it detects the symptoms but not the cause for cervical cancer, which is a persistent infection with carcinogenic human papillomavirus (HPV). It has now been firmly established that infection with high-risk papillomavirus (HPV) types is the primary cause of almost all cervical cancers.

                                                                    

Download → Inforamtion for labs             Download → Short Information        Download →Brochure for gynaecologists